Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 14, 2026, NDA 210875 (Kynmobi), held by Sumitomo Pharma Am, was first approved by FDA on May 21, 2020, with 2 approved supplements and 1 published complete response letter.
First approved: May 21, 2020
Review: Standard
Supplements approved: 2
Complete response letters: 1
Approvals and New Uses
The original application and every efficacy supplement, newest first; all 3 submissions below
Sep 22, 2022
Supplement 6Efficacy (new indication or use) · Standard review
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
